News & Updates

Show Multimedia Only

Tranexamic acid as good as norethisterone for HMB treatment

28 Nov 2024 by

Tranexamic acid was as effective as norethisterone in reducing menstrual blood loss and the duration of menstrual period in women with heavy menstrual bleeding (HMB), according to a study presented at RCOG 2024.

Tranexamic acid as good as norethisterone for HMB treatment

28 Nov 2024

Drugs vs surgery for weight loss: The better of 2 options

28 Nov 2024 by

In a first-of-a-kind meta-analysis comparing the efficacy and safety of different treatment options for obesity, weight loss surgery using the Roux-en-Y gastric bypass (RYGB) yields optimal weight loss than other surgical procedures or weight loss medications.

Drugs vs surgery for weight loss: The better of 2 options

28 Nov 2024

Inhaled analgesic provides adequate pain relief for minor gynae procedures

27 Nov 2024 by

Data presented at RCOG 2024 reflect the suitability of methoxyflurane – a short-acting analgesic delivered via a handheld, self-administered inhaler device – for use in the performance of minor gynaecology procedures.

Inhaled analgesic provides adequate pain relief for minor gynae procedures

27 Nov 2024

Add-on intrauterine misoprostol lowers PPH risk during caesarean delivery

27 Nov 2024 by

Adding intrauterine misoprostol to oxytocin significantly reduced the incidence of postpartum haemorrhage (PPH) in women who underwent caesarean section (CS) compared with oxytocin alone, according to a study presented at RCOG 2024.

Add-on intrauterine misoprostol lowers PPH risk during caesarean delivery

27 Nov 2024

Combination therapy with fosfomycin, azithromycin: A win for PPROM management

26 Nov 2024 by

In the management of preterm premature rupture of membranes (PPROM), a combination therapy of fosfomycin, clindamycin, and metronidazole has shown superiority over erythromycin plus metronidazole, while azithromycin has emerged as a promising alternative to erythromycin, with both regimens associated with favourable outcomes, as shown in two studies presented at RCOG 2024.

Combination therapy with fosfomycin, azithromycin: A win for PPROM management

26 Nov 2024

Does exposure to antihypertensive drugs increase cancer risk?

26 Nov 2024

Evidence from a large population-based study shows no consistent association between an increased risk of cancer and exposure to antihypertensive drugs.

Does exposure to antihypertensive drugs increase cancer risk?

26 Nov 2024

High-dose VE303 reduces ARG levels in individuals with CDI

26 Nov 2024 by

Treatment with high-dose VE303, a defined bacterial consortium composed of eight strains of commensal Clostridia, was associated with a significant reduction in antibiotic resistance genes (ARGs) among individuals with Clostridioides difficile infection (CDI), according to the phase II CONSORTIUM* study presented at IDWeek 2024.